Cited by 110Treatment of Major DepressionElectroconvulsive Therapy StudiesBipolar Disorder and Treatment

The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.

Augmentation strategies for treatment-resistant depression: a literature review: Augmentation strategies for TRD

Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., Lima, M. C. O.·2007·Journal of Clinical Pharmacy and Therapeutics

DOI 10.1111/j.1365-2710.2007.00846.x

Open this paper in CoChat — free account

Abstract

BACKGROUND: The large majority of depressed patients fail to remit on the first antidepressant prescribed. These patients with residual symptoms have higher relapse rates and poorer outcomes than those who remit. Treatment-resistant depression (TRD) is a therapeutic challenge for the clinician. Augmentation pharmacotherapy refers to the addition of drugs that are not standard antidepressants in order to enhance the effect of a classical antidepressant drug. The aim of this paper was to review the available evidence on the various augmenting agents that have been tested for efficacy in TRD. METHODS: Electronic databases and relevant textbooks were searched and the information retrieved was integrated in this review. RESULTS: Although augmentation strategies have been tested with various pharmacological agents, there are few controlled studies published. Lithium, triiodothyronine (T3), buspirone and pindolol have been most widely studied. Other agents include dopaminergic agents, atypical antipsychotics, psychostimulants, benzodiazepines/hypnotics, hormones and anticonvulsants. CONCLUSION: The augmentation therapy with the best evidence was the lithium-antidepressant combination, especially in patients not responding to tricyclic agents. However, good results have also been reported with augmentation strategies involving T3 and buspirone.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2710.2007.00846.x

Cites

176 of 176 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791
Untitled work
(1997) · PubMed · Cited by 727
Neuropsychopharmacology
Mathur, R. (2004) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10243_6 · Cited by 669

Show all 176 references

Research works printed but not linked: 1

Dunner, 2003, Adjunctive ziprasidone in treatment-resident depression: a pilot study

Sorted by citations

Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285
Serotonergic Drugs for Depression and Beyond
Stahl, S. M., Lee-Zimmerman, C., Cartwright, S., & Morrissette, D. A. (2013) · Current Drug Targets · doi:10.2174/1389450111314050007 · Cited by 273
Cognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252
Self-citation
Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study
Siwek, M., Dudek, D., Paul, I. A., Sowa-Kućma, M., Zięba, A., Popik, P., Pilc, A., & Nowak, G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.014 · Cited by 210
Therapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O. O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 212
Psychological therapies for treatment-resistant depression in adults
Ijaz, S., Davies, P., Williams, C. J., Kessler, D., Lewis, G., & Wiles, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010558.pub2 · Cited by 155
Defining Treatment-Resistant Depression: A Comprehensive Review of the Literature
Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M. M. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600310 · Cited by 130
Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial
Wiles, N., Thomas, L., Abel, A., Barnes, M., Carroll, F., Ridgway, N., Sherlock, S., Turner, N., Button, K., Odondi, L., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18310 · Cited by 127
The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Self-citation
Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults
MacQUEEN, G. M., Santaguida, P. L., Keshavarz, H., Jaworska, N., Levine, M., Beyene, J., & Raina, P. S. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716664885 · Cited by 130
Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations
Gabriel, F. C., de Melo, D. O., Fráguas, R., Leite-Santos, N. C., Silva, R. A. M., & Ribeiro, E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231700 · Cited by 122
Non-invasive brain stimulation in children: Applications and future directions
Rajapakse, T., & Kirton, A. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0116-3 · Cited by 123
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 104
Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine
Sillaber, I., Panhuysen, M., Henniger, M. S. H., Ohl, F., Kühne, C., Pütz, B., Pohl, T., Deussing, J. M., Páez-Pereda, M., & Holsboer, F. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1232-6 · Cited by 95
A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression
Zhang, C., Li, Z., Wu, Z., Chen, J., Wang, Z., Peng, D., Hong, W., Yuan, C., Wang, Z., Yu, S., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3297-0 · Cited by 95
Learning from negative feedback in patients with major depressive disorder is attenuated by SSRI antidepressants
Herzallah, M. M., Moustafa, A. A., Natsheh, J. Y., Abdellatif, S. M., Taha, M. B., Tayem, Y. I., Sehwail, M. A., Amleh, I., Petrides, G., Myers, C. E., et al. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00067 · Cited by 77
Augmentation strategies for treatment-resistant depression
Carvalho, A. F., Machado, J. R., & Cavalcante, J. L. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831be9ef · Cited by 78
Self-citation
Pharmacological interventions for treatment-resistant depression in adults
Davies, P. A., Ijaz, S., Williams, C. J., Kessler, D. S., Lewis, G., & Wiles, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010557.pub2 · Cited by 76
Glycogen Synthase Kinase-3 as a Therapeutic Target for Cognitive Dysfunction in Neuropsychiatric Disorders
O’Leary, O. F., & Nolan, Y. M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0213-z · Cited by 64
Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
Davidson, J., Zhang, W., Connor, K., Ji, J., Jobson, K. O., Lecrubier, Y., McFARLANE, A. C., Newport, D. J., Nutt, D., Osser, D. N., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108096505 · Cited by 67
Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test
Seo, M. K., Jeong, S., Seog, D., Lee, J. A., Lee, J.-H., Lee, Y. L., McIntyre, R. S., Park, S. W., & Lee, J. G. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.089 · Cited by 65
Repetitive Transcranial Magnetic Stimulation in Youth With Treatment Resistant Major Depression
MacMaster, F. P., Croarkin, P. E., Wilkes, T. C., McLellan, Q., Langevin, L. M., Jaworska, N., Swansburg, R. M., Jasaui, Y., Zewdie, E., Ciechanski, P., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00170 · Cited by 57
Resting-state brain alteration after a single dose of SSRI administration predicts 8-week remission of patients with major depressive disorder
Cheng, Y., Xu, J., Arnone, D., Nie, B., Yu, H., Jiang, H., Bai, Y., Luo, C., Campbell, R. A. A., Shan, B., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291716002440 · Cited by 51
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Psychotic Depression
Hamoda, H. M., & Osser, D. N. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220802277904 · Cited by 46
Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables
Perna, G., Alciati, A., Daccò, S., Grassi, M., & Caldirola, D. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0289 · Cited by 47
Serotonin–dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders
WOOD, M., & Wren, P. B. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00911-4 · Cited by 44
Experimentally induced thyrotoxicosis leads to increased connectivity in temporal lobe structures: A resting state fMRI study
Göttlich, M., Heldmann, M., Göbel, A., Dirk, A.-L., Brabant, G. E., & Münte, T. F. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.03.009 · Cited by 34
Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis
Li, D., Pain, O., Fabbri, C., Wong, W. L. E., Lo, C. W. H., Ripke, S., Cattaneo, A., Souery, D., Dernovšek, M. Z., Henigsberg, N., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02981-1 · Cited by 40
Chronobiological hypothalamic–pituitary–thyroid axis status and antidepressant outcome in major depression
Duval, F., Mokrani, M., Erb, A., Lopera, F. G., Alexa, C., Proudnikova, X., & Butucaru, I. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.05.005 · Cited by 33
L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial
Araminia, B., Shalbafan, M., Mortezaei, A., Shirazi, E., Ghaffari, S., Sahebolzamani, E., Mortazavi, S. H., Shariati, B., Ardebili, M. E., Aqamolaei, A., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.020 · Cited by 32
Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression
Drewniany, E., Han, J., Hancock, C., Jones, R. L., Lim, J., Gorgani, N. N., Sperry, J., Yu, H. J., & Raffa, R. B. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12238 · Cited by 32
Synergistic effect of [1H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-one] and antidepressant drugs in the mouse forced swimming test: Possible involvement of serotonergic pathway
Ergün, Y., Orhan, F. Ö., Özer, U. G., & Gişi, G. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.021 · Cited by 30
Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder
Brignone, M., Diamand, F., Painchault, C., & Takyar, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1128404 · Cited by 30
Approaches to Understanding and Addressing Treatment-Resistant Depression: A Scoping Review
Jenkins, E., & Goldner, E. M. (2012) · Depression Research and Treatment · doi:10.1155/2012/469680 · Cited by 29
Interplay between thyroxin, BDNF and GABA in injured neurons
Shulga, A., & Rivera, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.007 · Cited by 28
Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
Ivković, M., Damjanović, A., Jovanović, A., Cvetić, T., & Jašović‐Gašić, M. (2009) · PubMed · Cited by 28
Lithium augmentation of the effects of desipramine in a mouse model of treatment-resistant depression: A role for hippocampal cell proliferation
O’Leary, O. F., Zandy, S. L., Dinan, T. G., & Cryan, J. F. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.072 · Cited by 28
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Unipolar Nonpsychotic Depression
Giakoumatos, C. I., & Osser, D. N. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000197 · Cited by 27
Biomarkers of ketamine’s antidepressant effect: A clinical review of genetics, functional connectivity, and neurophysiology
Alario, A. A., & Niciu, M. J. (2021) · Chronic Stress · doi:10.1177/24705470211014210 · Cited by 26
Molecular serum signature of treatment resistant depression
Ruland, T., Chan, M. K., Stocki, P., Grosse, L., Rothermundt, M., Cooper, J. D., Arolt, V., & Bahn, S. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4348-0 · Cited by 26
Development of a Storytelling Video Self-Help Intervention Based on Acceptance and Commitment Therapy for Major Depression: Open Trial Results
Gaudiano, B. A., Davis, C. H., Miller, I. W., & Uebelacker, L. A. (2017) · Behavior Modification · doi:10.1177/0145445517738932 · Cited by 26
Dysfunction of Serotonergic and Dopaminergic Neuronal Systems in the Antidepressant-Resistant Impairment of Social Behaviors Induced by Social Defeat Stress Exposure as Juveniles
Hasegawa, S., Miyake, Y., Yoshimi, A., Mouri, A., Hida, H., Yamada, K., Ozaki, N., Nabeshima, T., & Noda, Y. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy038 · Cited by 26
Use of Mental Health Telemetry to Enhance Identification and Predictive Value of Early Changes During Augmentation Treatment of Major Depression
Schaffer, A., Kreindler, D., Reis, C., & Levitt, A. J. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31829e8359 · Cited by 22
Nutritional Interventions in Clinical Depression
Rechenberg, K. (2015) · Clinical Psychological Science · doi:10.1177/2167702614566815 · Cited by 22
Pharmacotherapy in depressed children and adolescents
Taurines, R., Gerlach, M., Warnke, A., Thome, J., & Wewetzer, C. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.600295 · Cited by 22
A Patient Stratification Approach to Identifying the Likelihood of Continued Chronic Depression and Relapse Following Treatment for Depression
Saunders, R., Cohen, Z. D., Ambler, G., DeRubeis, R. J., Wiles, N., Kessler, D., Gilbody, S., Hollon, S. D., Kendrick, T., Watkins, E., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121295 · Cited by 21
“This might involve consideration of more or less regular reviews with a clinician, more aggressive treatments or the augmentation of treatments to prevent chronic depression [30,68], or more conservative management and the use of relapse prevention focussed psychological therapies.”
Background
Choice of Treatment with Antidepressants: Influencing Factors
Himmerich, H., & Wranik, D. W. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523653 · Cited by 21
Use of medications by people with chronic fatigue syndrome and healthy persons: a population-based study of fatiguing illness in Georgia
Boneva, R. S., Lin, J.-M. S., Maloney, E. M., Jones, J. F., & Reeves, W. C. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-67 · Cited by 21
Mechanism of synergistic action on behavior, oxidative stress and inflammation following co-treatment with ketamine and different antidepressant classes
Réus, G. Z., Matias, B. I., Maciel, A. L., Abelaira, H. M., Ignácio, Z. M., de Moura, A. B., Matos, D., Danielski, L. G., Petronilho, F. C., Carvalho, A. F., et al. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.04.021 · Cited by 21
Self-citation
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder
Fagiolini, A. M., Cardoner, N., Pırıldar, Ş., Ittsakul, P., Ng, B., Duailibi, K., & Hindy, N. E. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2242264 · Cited by 21
Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: a protocol for a randomised, independent, pragmatic, multicentre, parallel-group, superiority clinical trial
Cipriani, A., Girlanda, F., Agrimi, E., Barichello, A., Beneduce, R., Bighelli, I., Bisoffi, G., Bisogno, A., Bortolaso, P., Boso, M., et al. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-212 · Cited by 20
Vasopressin drives aberrant myeloid differentiation of hematopoietic stem cells, contributing to depression in mice
Mou, R., Ma, J., Ju, X., Wu, Y., Chen, Q., Li, J., Shang, T., Chen, S., Yang, Y., Li, Y., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.09.018 · Cited by 20
A Cognitive Control Training as Add-On Treatment to Usual Care for Depressed Inpatients
Ferrari, G. R. A., Vanderhasselt, M., Rinck, M., Demeyer, I., Raedt, R. D., Beisel, S., Lindenmeyer, J., & Becker, E. S. (2021) · Cognitive Therapy and Research · doi:10.1007/s10608-020-10197-y · Cited by 17
Generalizability of treatment outcome prediction in major depressive disorder using structural MRI: A NeuroPharm study
Beliveau, V., Hedeboe, E., Fisher, P. M., Dam, V. H., Jørgensen, M. B., Frøkjær, V. G., Knudsen, G. M., & Ganz, M. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103224 · Cited by 17
Decreased Pretreatment Amygdalae Serotonin Transporter Binding in Unipolar Depression Remitters: A Prospective PET Study
Ananth, M. R., DeLorenzo, C., Yang, J., Mann, J. J., & Parsey, R. V. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.189654 · Cited by 17
Quality of clinical practice guidelines for inadequate response to first-line treatment for depression according to AGREE II checklist and comparison of recommendations: a systematic review
Gabriel, F. C., Stein, A. T., de Melo, D. O., Henrique Fontes-Mota, G. C., dos Santos, I. B., de Oliveira, A. F., Fráguas, R., & Ribeiro, E. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051918 · Cited by 15
Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta‐analysis
Giménez‐Palomo, A., Chamdal, A. K., Gottlieb, N., Lotfaliany, M., Jokinen, T., Bastawy, E. M., Adlington, K., Benachar, N., Dodd, S., Pacchiarotti, I., et al. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13728 · Cited by 15
Reviewing the mitochondrial dysfunction paradigm in rodent models as platforms for neuropsychiatric disease research
van Rensburg, D. J., Lindeque, J. Z., Harvey, B. H., & Steyn, S. F. (2022) · Mitochondrion · doi:10.1016/j.mito.2022.03.002 · Cited by 13
Investigating the (cost-) effectiveness of attention bias modification (ABM) for outpatients with major depressive disorder (MDD): a randomized controlled trial protocol
Ferrari, G. R. A., Becker, E. S., Smit, F., Rinck, M., & Spijker, J. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1085-1 · Cited by 14
Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials
Thase, M. E., Yeung, P. P., Rekeda, L., Liu, M., & Varughese, S. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000528 · Cited by 12
Augmentation Strategies
Thase, M. E. (2009) · CNS Spectrums · doi:10.1017/s1092852900003515 · Cited by 12
Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study
Seguı́, J., Lopez-Munoz, F. J., Álamo, C., Camarasa, X., García, P. G., & Pardo, A. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102641 · Cited by 12
Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?
Gervasoni, N., Aubry, J., Gex‐Fabry, M., Bertschy, G., & Bondolfi, G. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.11.005 · Cited by 12
Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis
Skelin, I., Yamane, F., & Dikšić, M. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.04.005 · Cited by 10
The Combined Treatment of Venlafaxine and Quetiapine for Treatment-Resistant Depression: A Clinical Study
Li, X., Xing, B., Yu, E., Chen, W., & Wu, H. (2013) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12070171 · Cited by 9
Current evidence for aripiprazole as augmentation therapy in major depressive disorder
Khan, A. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.10.1435 · Cited by 8
Protocol for a systematic review and meta-analysis of data from preclinical studies employing forced swimming test: an updateProtocol for a systematic review and meta-analysis of data from preclinical studies employing forced swimming test: an update
Ramos-Hryb, A. B., Bahor, Z., McCann, S., Sena, E. S., Macleod, M. R., & de Oliveira, C. L. (2019) · BMJ Open Science · doi:10.1136/bmjos-2017-000043 · Cited by 8
Clinical Guidelines of the Egyptian Psychiatric Association for the Management of Treatment-Resistant Unipolar Depression in Egypt
AbdelWahab, M. A., Okasha, T. A., Shaheen, M. O., Nasr, M., Molokheya, T., Omar, A. E., Rabie, M. A., Mikhael, V. S., Hamed, H., & Ali, M. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.797150 · Cited by 7
Lithium, Thyroid Hormones and Further Augmentation Strategies in Treatment‐resistant Depression
Haußmann, R., & Bauer, M. (2013) · Wiley eBooks · doi:10.1002/9781118556719.ch6 · Cited by 7
The Care of Patients With Complex Mood Disorders
Cordner, Z. A., MacKinnon, D. F., & DePaulo, J. R. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200007 · Cited by 6
The effects of brain serotonin deficiency on the behavioral and neurogenesis-promoting effects of voluntary exercise in tryptophan hydroxylase 2 (R439H) knock-in mice
Warner, A. K., Iskander, L., Allen, K., Quatela, I., Borrelli, H., & Sachs, B. D. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110082 · Cited by 7
Neuroendocrine Assessment of Dopaminergic Function during Antidepressant Treatment in Major Depressed Patients
Duval, F., Mokrani, M., Erb, A., Lopera, F. G., Dănilă, V., & Tomsa, M. (2021) · Brain Sciences · doi:10.3390/brainsci11040425 · Cited by 5
Psychological therapies for treatment-resistant depression in adults
Wiles, N., Williams, C. J., Kessler, D. S., & Lewis, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010558 · Cited by 5
Managing high‐acuity‐depressed adults in primary care
Sobczak, J. A. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00422.x · Cited by 4
Oxazepam and temazepam attenuate paroxetine-induced elevation of serotonin levels in guinea-pig hippocampus
Cremers, T. I. F. H., Dremencov, E., Bosker, F. J., & Westerink, B. H. C. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570999109x · Cited by 4
Brain Stimulation in Childhood Mental Health
MacMaster, F. P., Sembo, M., Ma, K., & Croarkin, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802001-2.00016-3 · Cited by 4
Pharmacological interventions for treatment-resistant depression in adults
Williams, C. J., Taylor, M., Kessler, D. S., Lewis, G., & Wiles, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010557 · Cited by 4
A Randomized Controlled Pilot Study Exploring the Additive Clinical Effect of Cognitive Bias Modification-Memory in Depressed Inpatients
Vrijsen, J. N., Windbergs, H., Becker, E. S., Scherbaum, N., Müller, B. W., & Tendolkar, I. (2023) · Cognitive Therapy and Research · doi:10.1007/s10608-023-10452-y · Cited by 3
Structural Brain Connectivity and Treatment Improvement in Mood Disorder
Dam, S., Batail, J.-M. V., Robert, G. H., Drapier, D., Maurel, P., & Coloigner, J. (2024) · Brain Connectivity · doi:10.1089/brain.2023.0063 · Cited by 3
Pharmakologische Behandlungsmöglichkeiten bei therapieresistenter Depression
Kahl, K. G. (2012) · Nervenheilkunde · doi:10.1055/s-0038-1628182 · Cited by 3
Can low-dose propranolol induce a manic syndrome? Case report of an unexpected side effect
Shahrbabaki, M. E., Estilaee, F., & Shahrbabaki, M. E. (2012) · Acta Neuropsychiatrica · doi:10.1111/acn.12021 · Cited by 3
Defining and Differentiating Treatment-Resistant Depression
Treviño, K. (2012) · Cited by 3
Treatment of neuropsychiatric symptoms associated with euthyroid Hashimoto thyroiditis with antidepressants: a case report
Andreou, C., Bozikas, V. P., Lagoudis, A., Paspali, D., & Fokas, K. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.07.005 · Cited by 2
Combination Strategies in Treatment-Resistant Depression
Lopez-Munoz, F. J., Álamo, C., & García‐García, P. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_28 · Cited by 2
Depressive Störungen
Taurines, R., Wewetzer, C., & Schulte‐Körne, G. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_14 · Cited by 1
Research Priorities in Late-Life Mood Disorders
Dow, B., Lin, X., Tinney, J., Harambous, B., & Ames, D. J. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796816.003.0002 · Cited by 1
Depressive Störungen
Taurines, R., & Wewetzer, C. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_14 · Cited by 1
Integrative medicine approaches to chronic depression: case studies of the recovery process with a three-step path to recovery and significant cure
Itamura, R. (2022) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2022-0034 · Cited by 1
Therapeutic Approaches to Tackle the Challenge of Depression That Is Resistant to Treatment–A Narrative Review
Rafe, M. R., Waris, A., & Saha, P. (2025) · Health Science Reports · doi:10.1002/hsr2.70370 · Cited by 3
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Antidepressant Combination Strategies for Major Depressive Disorder
Carvalho, A. F., Macêdo, D. S., Hyphantis, T. N., & McIntyre, R. S. (2012) · Springer eBooks · doi:10.1007/978-94-007-5799-8_10
Self-citation
Comparative efficacy and acceptability of seven augmentation agents for treatment-resistant depression: A multiple-treatments meta-analysis
Qi, H., Wang, X., & Huang, S. (2014) · South African Journal of Psychiatry · doi:10.7196/sajp.530
Effects of Remission and Genetic Variation on Brain Structure in Treatment-Resistant Major Depressive Disorder: A Prospective, Longitudinal Imaging Study
Phillips, J. L. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-2800
Treatment-resistant depression and the elephant in the room
Jenkins, E. (2010) · Summit (Simon Fraser University)
중증 정신 질환 환자에서의 약물 순응도 향상
노대영, 장진구, & 김찬형 (2012) · 대한정신약물학회지
Algorithms: STAR*D, Positives, Negatives, and Implications for Clinical Practice
Huynh, N., & McIntyre, R. S. (2009) · doi:10.3109/9781420084887-7
The cognitive correlates of major depressive disorder and administration of SSRI antidepressants
Herzallah, M. M. (2015) · doi:10.7282/t38w3g5q
ENVOLVIMENTO DE MECANISMOS DOPAMINÉRGICOS NA ATIVIDADE ANTIDEPRESSIVA DA LEPTINA NO COMPORTAMENTO TIPO-DEPRESSÃO INDUZIDO POR LPS EM CAMUNDONGOS
Cordeiro, R. C. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
Sanacora, G., Kitay, B. M., & Wilkinson, S. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00035-4

Authors: Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O.
Affiliations: Universidade Federal do Ceará (BR)
Henry Ford Health (US)
ORCID: Carvalho, A. F.
Cavalcante, J. L.
Lima, M. C. O.
Venue: Journal of Clinical Pharmacy and Therapeutics
Publisher: Wiley
Published: 2007-09-14
Volume: 32
Issue: 5
Pages: 415-428
ISSN: 0269-4727 (ISSN-L)
1365-2710
DOI: 10.1111/j.1365-2710.2007.00846.x
OpenAlex: W1623415077
Cited by: 110
References: 176
Citations by year: 2026: 1 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 4 · 2019: 8 · 2018: 2 · 2017: 3 · 2016: 8 · 2015: 6 · 2014: 10 · 2013: 12 · 2012: 10
FWCI: 0.77
Type: journal article
Language: en
Open access: closed
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2909 d)
Locations: Journal of Clinical Pharmacy and Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: treatment-resistant depression, augmentation therapy, antidepressant augmentation, lithium, triiodothyronine, buspirone, pindolol, atypical antipsychotics, psychostimulants, benzodiazepines, antiepileptic drugs, tricyclic antidepressants, residual depressive symptoms
MeSH terms: Central Nervous System Stimulants, Anticonvulsants, Antidepressive Agents, Benzodiazepines, Buspirone, Depressive Disorder, Drug Resistance, Drug Synergism, Drug Therapy, Combination, Humans, Hypnotics and Sedatives, Pindolol, Antipsychotic Agents, Triiodothyronine, Dopamine Agents, Lithium Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Augmentation strategies for treatment-resistant depression: a literature review: Augmentation strategies for TRD

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks